



## **Autolus Therapeutics to Participate in Upcoming Investor Conferences in June**

May 28, 2019 at 4:55 PM EDT

LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in the following investor conferences in June:

- Dr. Christian Itin, chairman and chief executive officer, will present at the Jefferies 2019 Healthcare Conference in New York on Wednesday, June 5 at 2:30 p.m. ET and will host one-on-one meetings with attendees. A live webcast of the presentation will be available on the investor relations section of Autolus' website at <https://www.autolus.com>. An archived replay will be available on the company's website for a period of 90 days after the conference.
- Andrew Oakley, chief financial officer, and Christopher Vann, chief operating officer, will participate in the Goldman Sachs 40<sup>th</sup> Annual Global Healthcare Conference in Rancho Palos Verdes, Calif., hosting one-on-one meetings on Tuesday, June 11, 2019.

### **About Autolus Therapeutics plc**

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: <https://www.autolus.com>.

#### **Investor contact:**

Susan A. Noonan  
S.A. Noonan Communications  
+1-212-966-3650  
[susan@sanoonan.com](mailto:susan@sanoonan.com)

#### **Media contacts:**

Silvia Taylor  
Vice President, Corporate Affairs and Communications  
Autolus  
+1-240-801-3850  
[s.taylor@autolus.com](mailto:s.taylor@autolus.com)

Julia Wilson  
JW Communications  
+44 (0) 7818 430877  
[j.wilson@autolus.com](mailto:j.wilson@autolus.com)

Source: Autolus Therapeutics plc